Nordic virus monitoring and diagnostics’ companies Cavidi and BioPorto have initiated a joint collaboration to utilize Cavidi’s ZIVA system to enable antigen detection of an existing SARS CoV-2 infection as well as antibody detection of a past infection. The tests will run on ZIVA, a fully automated instrument for distributed, front line rapid testing scale-up.
The joint development plan will automate BioPorto rapid test reagents on a serology platform by Cavidi for frontline deployment of SARS-CoV-2 testing. The Danish and Swedish companies will each bring their proprietary virus detection technologies and extensive assay development experience to the Nordic undertaking to enable the testing system delivery in 2020.
Cavidi CEO John Reisky de Dubnic said: “The Nordic life science community is stepping up with unprecedented collaboration efforts in the fight against the COVID19 pandemic. We are delighted to partner with BioPorto on this diagnostic development to bring both virus and antibody testing to front line deployment using our fit for purpose ZIVA instrument.”
“Partnering with Cavidi in fighting the COVID19 pandemic will add a fully automated instrument platform for quantitative testing which complements BioPorto Diagnostic’s current development of the COVID19 gRAD rapid lateral flow test”, says Jan Kuhlmann, BioPorto Diagnostic’s COO.
John Reisky de Dubnic, Chairman Cavidi AB
M: +46 73 35 50 145
Jan Kuhlmann, Ph.D, COO BioPorto Diagnostics
M: + 45 53 80 00 38
We are experts in virus monitoring with over 30 years of experience on the front line of the HIV pandemic. We focus on clinical diagnostics for viral monitoring to slow infectivity and quantify viral fitness used in research. Virus monitoring is an essential tool in viral pandemic wars past, present, and future. Cavidi is headquartered in Uppsala, Sweden https://cavidi.se/
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark, with US headquarters in Needham, Massachusetts, and is listed on the NASDAQ Copenhagen stock exchange [CPH: BIOPOR].